Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Reports Sharp Rise in Q3 Revenues

NEW YORK (GenomeWeb News) – Reporting for the first time as a public company, synthetic biology company Intrexon said after the close of the market on Thursday that revenues in its third quarter more than doubled year over year.

Total revenues for the three months ended Sept. 30 reached $6.1 million, up from $2.9 million a year ago, driven by an uptick in collaboration revenues, which increased to $6.0 million from $2.9 million a year ago. Other revenues were up to $105,000 from $21,000.

The Germantown, Md.-based firm said that the rise in collaboration revenues were due mainly to the recognition of deferred revenue for upfront payments received from collaborations. Intrexon also received revenues for R&D services performed under the collaborations during the recently completed quarter.

The company posted a profit of $15.0 million, or $.15 per share, in the quarter, compared to a net loss of $20.5 million, or $4.66 per share, a year ago.

It reduced its R&D expenses 24 percent to $10.8 million from $14.3 million, but increased its SG&A spending 48 percent to $7.4 million from $5.0 million.

The lower R&D costs resulted from decreases in personnel expenses and lab supplies as certain positions were eliminated due to improvements in production processes and the centralization of some R&D functions.

SG&A costs rose primarily as a result of increases in personnel costs for new employees as Intrexon prepared to go public. The company completed an initial public offering in August.

Intrexon said that the SG&A expenses also included the cost of AquaBounty Technologies' employees. In March, Intrexon increased its ownership interest in the aquaculture biotechnology shop and gained control over the company.

In Friday morning trading, shares of Intrexon on the New York Stock Exchange were up 9 percent at $19.49.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.